January 31, 2025

Raymond James Ltd. facilitates $30 million equity financing for Medexus Pharmaceuticals Inc.

Goodmans LLP acted for Raymond James Ltd., as lead underwriter and sole bookrunner, in connection with the $30 million equity financing of Medexus Pharmaceuticals Inc. by way of shelf prospectus offering.

The overnight marketed underwritten offering comprised of 7,500,000 common shares of Medexus at a public offering price of $4.00 per common share. Medexus expects that the net proceeds of the offering will be used: (i) to repay a US$2.5 million credit received from medac in September 2021 and pay a portion of the milestone payment amount to medac, and (ii) for working capital and general corporate purposes, which may include funding the company's ongoing business development activities and initiatives.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions.

"Goodmans brings independence, governance expertise and deep capital markets knowledge to conflicts-sensitive mandates. Goodmans is consistently responsive and well-organised, and communicated clearly throughout." — Chambers Canada
"Goodmans brings a strong team to the table with a clear sense of pragmatism on highly complicated transactions." — Chambers Canada
"Goodmans capital markets team consistently delivers sound, practical advice with a sharp attention to detail on the granular nuances that matter in complex transactions." — Chambers Canada
"Goodmans has deep experience in capital markets and in the REIT space. Their service and responsiveness levels are also very high." — Chambers Canada
Goodmans LLP houses a full-service capital markets practice... Among its core strong suits, the group is arguably best known for its strength in SPACs, REITs and IPOs... — The Legal 500 Canada
"The team is very professional, solves problems efficiently and is very hard-working. It is a great pleasure and privilege to work with the team on cross-border transactions and multi-jurisdictional projects." — Legal 500 Canada
"It is one of our trusted and preferred legal firms when we go to select specific counsel. It is a leader in capital markets, and we trust the group's view and know that it works well." — Chambers Canada
A prominent player in REITs and SPAC-related offerings, also bearing an impressive record in cross-border and cannabis-related matters. — The Legal 500 Canada
Clients note, "They have an exceptional ability to understand the root of the issue and figure out realistic, step-by-step approaches to solve problems." — Chambers Canada
A distinguished practice valued for advising major REITs and financial institutions on innovative capital markets transactions. — Chambers Canada
On the Capital Markets group, one client says, "deep strength and expertise at all levels...nothing can replace stability and the fact that I have worked with Goodmans on both sides of the table since the early 2000’s." — Legal 500 Canada
One interviewee reported, "The Goodmans team as a whole is excellent," adding: "The lawyers are very responsive and get the job done. It is of great assurance to have them as our legal advisers." — Chambers Canada
Clients comment Goodmans Capital Markets team has "Deep experience, based upon decades of leadership in the sector." — IFLR1000
A client notes, "The lawyers that I have worked with at Goodmans are extremely professional, knowledgeable, creative and excellent service providers. The matters that we have worked on were extremely complicated and required high level of ability to combine understanding of our business objectives with legal analysis." — IFLR1000
Clients note the team's "institutional knowledge is very deep" and stated: "It's like they're part of the team they work with. They're extremely responsive." — Chambers Global

Practices

Industries

Raymond James Ltd. facilitates $30 million equity financing for Medexus Pharmaceuticals Inc.

Site Search

Raymond James Ltd. facilitates $30 million equity financing for Medexus Pharmaceuticals Inc.

Expertise

Featured Work